Clinical trial
Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma
NCT00404248 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- February 29, 2012
- Enrollment
- 35 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
brain and central nervous system tumors